Endothelial maintenance in health and disease: Importance of sex differences

Pharmacological Research

Volumn 119, Issue , 2017, Pages 48-60

  Mudrovcic, Neja ^a   Arefin, Samsul ^a   Van Craenenbroeck, Amaryllis H ^a,b,c   Kublickiene, Karolina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cardiovascular; Endothelium; Hormones; Nitric oxide; Sex

Indexed keywords

ANDROGEN RECEPTOR; CYTOCHROME P450 2C9; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN RECEPTOR ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; PHOSPHOLIPASE A2; PROSTAGLANDIN SYNTHASE; NITRIC OXIDE;

CALCIUM CELL LEVEL; CELL FUNCTION; CELL MEMBRANE POTENTIAL; CELL MIGRATION; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; MEAN ARTERIAL PRESSURE; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PREECLAMPSIA; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SEX DIFFERENCE; SHEAR STRESS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE TONE; UPREGULATION; WEIGHT REDUCTION; ANIMAL; CARDIOVASCULAR DISEASES; FEMALE; HOMEOSTASIS; MALE; METABOLISM; PATHOLOGY; POLYCYSTIC OVARY SYNDROME; PRE-ECLAMPSIA; PREGNANCY; RENAL INSUFFICIENCY, CHRONIC; SEXUAL DEVELOPMENT; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; FEMALE; HOMEOSTASIS; HUMANS; MALE; NITRIC OXIDE; POLYCYSTIC OVARY SYNDROME; PRE-ECLAMPSIA; PREGNANCY; RENAL INSUFFICIENCY, CHRONIC; SEX CHARACTERISTICS; SEX FACTORS;

EID: 85011345073     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.01.011     Document Type: Review

References (230)

1. [1] Mosca, L., Barrett-Connor, E., Kass Wenger, N., Sex/gender differences in cardiovascular disease prevention. Circulation 124 (2011), 2145–2154.
2. [2] Jousilahti, P., Vartiainen, E., Tuomilehto, J., Puska, P., Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 99 (1999), 1165–1172.
3. [3] Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. Heart disease and stroke statistics—2015 update. Circulation 131 (2015), e29–322.
4. [4] Moller-Leimkuhler, A.M., Gender differences in cardiovascular disease and comorbid depression. Dialog. Clin. Neurosci. 9 (2007), 71–83.
5. [5] Regitz-Zagrosek, V., Oertelt-Prigione, S., Prescott, E., Franconi, F., Gerdts, E., Foryst-Ludwig, A., et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur. Heart J. 37 (2015), 24–34.
6. [6] Ross, R., Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 11 (1999), 115–126.
7. [7] Luksha, L., Kublickiene, K., Implications for endothelium-derived hyperpolarizing factor (EDHF) in women's cardiovascular health. Curr. Womens Health Rev. 1 (2005), 67–78.
8. [8] Luksha, L., Agewall, S., Kublickiene, K., Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis 202 (2009), 330–344, 10.1016/j.atherosclerosis.2008.06.008.
9. [9] Matsumoto, T., Wakabayashi, K., Kobayashi, T., Kamata, K., Alterations in vascular endothelial function in the aorta and mesenteric artery in type II diabetic rats. Can. J. Physiol. Pharmacol. 82 (2004), 175–182, 10.1139/y04-002.
10. [10] Katz, S.D., Krum, H., Acetylcholine-mediated vasodilation in the forearm circulation of patients with heart failure: indirect evidence for the role of endothelium-derived hyperpolarizing factor. Am. J. Cardiol. 87 (2001), 1089–1092.
11. [11] Scotland, R.S., Madhani, M., Chauhan, S., Moncada, S., Andresen, J., Nilsson, H., et al. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation 111 (2005), 796–803, 10.1161/01.CIR.0000155238.70797.4E.
12. [12] McCulloch, A.I., Randall, M.D., Sex differences in the relative contributions of nitric oxide and EDHF to agonist-stimulated endothelium-dependent relaxations in the rat isolated mesenteric arterial bed. Br. J. Pharmacol. 123 (1998), 1700–1706, 10.1038/sj.bjp.0701781.
13. [13] Pak, K.J., Geary, G.G., Duckles, S.P., Krause, D.N., Male-female differences in the relative contribution of endothelial vasodilators released by rat tail artery. Life Sci. 71 (2002), 1633–1642.
14. [14] Sato, A., Miura, H., Liu, Y., Somberg, L.B., Otterson, M.F., Demeure, M.J., et al. Effect of gender on endothelium-dependent dilation to bradykinin in human adipose microvessels. Am. J. Physiol. Heart Circ. Physiol. 283 (2002), H845–52, 10.1152/ajpheart.00160.2002.
15. [15] Wellman, G.C., Bonev, A.D., Nelson, M.T., Brayden, J.E., Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca(2+)-dependent K+ channels. Circ. Res. 79 (1996), 1024–1030.
16. [16] Nawate, S., Fukao, M., Sakuma, I., Soma, T., Nagai, K., Takikawa, O., et al. Reciprocal changes in endothelium-derived hyperpolarizing factor- and nitric oxide-system in the mesenteric artery of adult female rats following ovariectomy. Br. J. Pharmacol. 144 (2005), 178–189, 10.1038/sj.bjp.0706091.
17. [17] Addis, R., Campesi, I., Fois, M., Capobianco, G., Dessole, S., Fenu, G., et al. Human umbilical endothelial cells (HUVECs) have a sex: characterisation of the phenotype of male and female cells. Biol. Sex Differ. 5 (2014), 1–12, 10.1186/s13293-014-0018-2.
18. [18] Lorenz, M., Koschate, J., Kaufmann, K., Kreye, C., Mertens, M., Kuebler, W.M., et al. Does cellular sex matter? Dimorphic transcriptional differences between female and male endothelial cells. Atherosclerosis 240 (2015), 61–72, 10.1016/j.atherosclerosis.2015.02.018.
19. [19] Miller, V.M., Kaplan, J.R., Schork, N.J., Ouyang, P., Berga, S.L., Wenger, N.K., et al. Strategies and methods to study sex differences in cardiovascular structure and function: a guide for basic scientists. Biol. Sex Differ., 2, 2011, 14, 10.1186/2042-6410-2-14.
20. [20] Moncada, S., Palmer, R.M., Higgs, E.A., Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43 (1991), 109–142.
21. [21] Busse, R., Fleming, I., Regulation and functional consequences of endothelial nitric oxide formation. Ann. Med. 27 (1995), 331–340, 10.3109/07853899509002586.
22. [22] Semenza, G.L., New insights into nNOS regulation of vascular homeostasis. J. Clin. Invest. 115 (2005), 2976–2978, 10.1172/JCI26792.
23. [23] Hauser, B., Radermacher, P., Thiemermann, C., Matejovic, M., Nitric oxide, bacteria, and host defense in sepsis: who needs what?. Shock 22 (2004), 588–590.
24. [24] Villar, I.C., Francis, S., Webb, A., Hobbs, A.J., Ahluwalia, A., Novel aspects of endothelium-dependent regulation of vascular tone. Kidney Int. 70 (2006), 840–853, 10.1038/sj.ki.5001680.
25. [25] Luo, S., Lei, H., Qin, H., Xia, Y., Molecular mechanisms of endothelial NO synthase uncoupling. Curr. Pharm. Des. 20 (2014), 3548–3553.
26. [26] Luscher, T.F., Richard, V., Tschudi, M., Yang, Z., Boulanger, C., Endothelial control of vascular tone in large and small Coronary arteries. JACC 15 (1990), 519–527.
27. [27] Vásquez-Vivar, J., Kalyanaraman, B., Martásek, P., Hogg, N., Masters, B.S.S., Karoui, H., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 9220–9225.
28. [28] Davidge, S.T., Ojimba, J., Mclaughlin, M.K., Vascular function in the vitamin E-deprived rat an interaction between nitric oxide and superoxide anions. Hypertension 31 (1998), 830–835.
29. [29] Yang, Z., Ming, X., Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res. 4 (2006), 53–65.
30. [30] Popp, R., Gogelein, H., A calcium and ATP sensitive nonselective cation channel in the antiluminal membrane of rat cerebral capillary endothelial cells. Biochim. Biophys. Acta 1108 (1992), 59–66.
31. [31] Taylor, S.G., Southerton, J.S., Weston, A.H., Baker, J.R., Endothelium-dependent effects of acetylcholine in rat aorta: a comparison with sodium nitroprusside and cromakalim. Br. J. Pharmacol. 94 (1988), 853–863.
32. [32] Mombouli, J.V., Bissiriou, I., Agboton, V., Vanhoutte, P.M., Endothelium-derived hyperpolarizing factor: a key mediator of the vasodilator action of bradykinin. Immunopharmacology 33 (1996), 46–50.
33. [33] Luksha, L., Nisell, H., Kublickiene, K., The mechanism of EDHF-mediated responses in subcutaneous small arteries from healthy pregnant women. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286 (2004), R1102–9, 10.1152/ajpregu.00550.2003.
34. [34] Mitchell, J.A., Ali, F., Bailey, L., Moreno, L., Harrington, L.S., Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp. Physiol. 93 (2007), 141–147, 10.1113/expphysiol.2007.038588.
35. [35] Frangos, J.A., Eskin, S.G., McIntire, L.V., Ives, C.L., Flow effects on prostacyclin production by cultured human endothelial cells. Science 227 (1985), 1477–1479.
36. [36] Carter, T.D., Hallam, T.J., Cusack, N.J., Pearson, J.D., Regulation of P2y-purinoceptor-mediated prostacyclin release from human endothelial cells by cytoplasmic calcium concentration. Br. J. Pharmacol. 95 (1988), 1181–1190.
37. [37] Chang, J., Musser, J.H., McGregor, H., Phospholipase A2: function and pharmacological regulation. Biochem. Pharmacol. 36 (1987), 2429–2436.
38. [38] Imig, J.D., Zou, A.P., Stec, D.E., Harder, D.R., Falck, J.R., Roman, R.J., Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am. J. Physiol. 270 (1996), R217–27.
39. [39] Moncada, S., Vane, J.R., Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol. Rev. 30 (1978), 293–331.
40. [40] Sugatani, J., Miwa, M., Komiyama, Y., Ito, S., High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J. Lipid Mediat. Cell Signal. 13 (1996), 73–88.
41. [41] Samuelsson, B., Goldyne, M., Granstrom, E., Hamberg, M., Hammarstrom, S., Malmsten, C., Prostaglandins and thromboxanes. Annu. Rev. Biochem 47 (1978), 997–1029, 10.1146/annurev.bi.47.070178.005025.
42. [42] Chataigneau, T., Feletou, M., Huang, P.L., Fishman, M.C., Duhault, J., Vanhoutte, P.M., Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br. J. Pharmacol. 126 (1999), 219–226, 10.1038/sj.bjp.0702300.
43. [43] Kasza, Z., Fetalvero, K.M., Ding, M., Wagner, R.J., Acs, K., Guzman, A.K., et al. Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J. Mol. Cell. Cardiol. 46 (2009), 682–694, 10.1016/j.yjmcc.2009.01.006.
44. [44] Masaki, T., The discovery, the present state, and the future prospects of endothelin. J. Cardiovasc. Pharmacol. 13:Suppl. 5 (1989), S1–S4 discussion S18.
45. [45] Bohm, F., Pernow, J., The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc. Res. 76 (2007), 8–18, 10.1016/j.cardiores.2007.06.004.
46. [46] Levin, E.R., Endothelins. N. Engl. J. Med. 333 (1995), 356–363, 10.1056/NEJM199508103330607.
47. [47] Rubanyi, G.M., Polokoff, M.A., Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46 (1994), 325–415.
48. [48] Dammanahalli, K.J., Sun, Z., Endothelins and NADPH oxidases in the cardiovascular system. Clin. Exp. Pharmacol. Physiol. 35 (2008), 2–6, 10.1111/j.1440-1681.2007.04830.x.
49. [49] de Nucci, G., Thomas, R., D'Orleans-Juste, P., Antunes, E., Walder, C., Warner, T.D., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. U. S. A. 85 (1988), 9797–9800.
50. [50] Taddei, S., Vanhoutte, P.M., Endothelium-dependent contractions to endothelin in the rat aorta are mediated by thromboxane A2. J. Cardiovasc. Pharmacol. 22:Suppl. 8 (1993), S328–31.
51. [51] Haynes, W.G., Webb, D.J., Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet (London, England) 344 (1994), 852–854.
52. [52] Kyriakides, Z.S., Kremastinos, D.T., Bofilis, E., Tousoulis, D., Antoniadis, A., Webb, D.J., Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography. Heart 84 (2000), 176–182.
53. [53] Pernow, J., Hemsen, A., Lundberg, J.M., Nowak, J., Kaijser, L., Potent vasoconstrictor effects and clearance of endothelin in the human forearm. Acta Physiol. Scand. 141 (1991), 319–324, 10.1111/j.1748-1716.1991.tb09087.x.
54. [54] Weitzberg, E., Ahlborg, G., Lundberg, J.M., Differences in vascular effects and removal of endothelin-1 in human lung, brain, and skeletal muscle. Clin. Physiol. 13 (1993), 653–662.
55. [55] Pernow, J., Kaijser, L., Lundberg, J.M., Ahlborg, G., Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 94 (1996), 2077–2082.
56. [56] Barton, M., Aging and endothelin: determinants of disease. Life Sci. 118 (2014), 97–109, 10.1016/j.lfs.2014.09.009.
57. [57] Malorni, W., Campesi, I., Straface, E., Vella, S., Franconi, F., Redox features of the cell: a gender perspective. Antioxid. Redox Signal. 9 (2007), 1779–1801, 10.1089/ars.2007.1596.
58. [58] Wang, J., Bingaman, S., Huxley, V.H., Intrinsic sex-specific differences in microvascular endothelial cell phosphodiesterases. Am. J. Physiol. Heart Circ. Physiol. 298 (2010), H1146–54, 10.1152/ajpheart.00252.2009.
59. [59] Annibalini, G., Agostini, D., Calcabrini, C., Martinelli, C., Colombo, E., Guescini, M., et al. Effects of sex hormones on inflammatory response in male and female vascular endothelial cells. J. Endocrinol. Invest. 37 (2014), 861–869, 10.1007/s40618-014-0118-1.
60. [60] Death, A.K., McGrath, K.C.Y., Sader, M.A., Nakhla, S., Jessup, W., Handelsman, D.J., et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor-KappaB-dependent pathway. Endocrinology 145 (2004), 1889–1897, 10.1210/en.2003-0789.
61. [61] Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997), 964–967.
62. [62] Van Craenenbroeck, E.M., Van Craenenbroeck, A.H., van Ierssel, S., Bruyndonckx, L., Hoymans, V.Y., Vrints, C.J., et al. Quantification of circulating CD34+/KDR+/CD45dim endothelial progenitor cells: analytical considerations. Int. J. Cardiol. 167 (2013), 1688–1695, 10.1016/j.ijcard.2012.10.047.
63. [63] Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18 (1999), 3964–3972, 10.1093/emboj/18.14.3964.
64. [64] Li, B., Sharpe, E.E., Maupin, A.B., Teleron, A.A., Pyle, A.L., Carmeliet, P., et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 20 (2006), 1495–1497, 10.1096/fj.05-5137fje.
65. [65] Hur, J., Yoon, C.-H., Kim, H.-S., Choi, J.-H., Kang, H.-J., Hwang, K.-K., et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 288–293, 10.1161/01.ATV.0000114236.77009.06.
66. [66] Zhang, M., Malik, A.B., Rehman, J., Endothelial progenitor cells and vascular repair. Curr. Opin. Hematol. 21 (2014), 224–228, 10.1097/MOH.0000000000000041.
67. [67] Vasa, M., Fichtlscherer, S., Aicher, A., Adler, K., Urbich, C., Martin, H., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89 (2001), E1–E7.
68. [68] Werner, N., Kosiol, S., Schiegl, T., Ahlers, P., Walenta, K., Link, A., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med. 353 (2005), 999–1007, 10.1056/NEJMoa043814.
69. [69] Schmidt-Lucke, C., Rossig, L., Fichtlscherer, S., Vasa, M., Britten, M., Kamper, U., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111 (2005), 2981–2987, 10.1161/CIRCULATIONAHA.104.504340.
70. [70] Fadini, G.P., Coracina, A., Baesso, I., Agostini, C., Tiengo, A., Avogaro, A., et al. Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Stroke 37 (2006), 2277–2282, 10.1161/01.STR.0000236064.19293.79.
71. [71] Lemieux, C., Cloutier, I., Tanguay, J., Menstrual cycle influences endothelial progenitor cell regulation: a link to gender differences in vascular protection? ☆. Int. J. Cardiol. 136 (2009), 200–210, 10.1016/j.ijcard.2008.04.054.
72. [72] Rousseau, A., Sc, M., Ayoubi, F., Sc, M., Deveaux, C., Pharm, D., et al. Impact of age and gender interaction on circulating endothelial progenitor cells in healthy subjects. Fertil. Steril. 93 (2010), 843–846, 10.1016/j.fertnstert.2008.10.062.
73. [73] Herrmann, J.L., Abarbanell, A.M., Weil, B.R., Manukyan, M.C., Poynter, J.A., Wang, Y., et al. Gender dimorphisms in progenitor and stem cell function in cardiovascular disease. Cardiovasc Trans Res 2009 (2016), 103–113, 10.1007/s12265-009-9149-y.
74. [74] Hoetzer, G.L., Maceneaney, O.J., Irmiger, H.M., Keith, R., Van Guilder, G.P., Stauffer, B.L., et al. Gender differences in circulating endothelial progenitor cell colony-forming capacity and migratory activity in middle-aged adults. Am. J. Cardiol. 99 (2007), 46–48, 10.1016/j.amjcard.2006.07.061.
75. [75] Iwakura, A., Luedemann, C., Shastry, S., Hanley, A., Kearney, M., Aikawa, R., et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 108 (2003), 3115–3121, 10.1161/01.CIR.0000106906.56972.83.
76. [76] Campesi, I., Capobianco, G., Dessole, S., Occhioni, S., Montella, A., Franconi, F., Estrogenic compounds have divergent effects on human endothelial progenitor cell migration according to sex of the donor. J. Vasc. Res. 52 (2015), 273–278, 10.1159/000443403.
77. [77] Foresta, C., Caretta, N., Lana, A., De Toni, L., Biagioli, A., Ferlin, A., et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J. Clin. Endocrinol. Metab. 91 (2006), 4599–4602, 10.1210/jc.2006-0763.
78. [78] Foresta, C., Zuccarello, D., De Toni, L., Garolla, A., Caretta, N., Ferlin, A., Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin. Endocrinol. (Oxf.) 68 (2008), 284–289, 10.1111/j.1365-2265.2007.03036.x.
79. [79] Halcox, J.P.J., Schenke, W.H., Zalos, G., Mincemoyer, R., Prasad, A., Waclawiw, M.A., et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106 (2002), 653–658, 10.1161/01.CIR.0000025404.78001.D8.
80. [80] Flammer, A.J., Anderson, T., Celermajer, D.S., Creager, M.A., Deanfield, J., Ganz, P., et al. The assessment of endothelial function: from research into clinical practice. Circulation 126 (2012), 753–767, 10.1161/CIRCULATIONAHA.112.093245.
81. [81] Joannides, R., Haefeli, W.E., Linder, L., Richard, V., Bakkali, E.H., Thuillez, C., et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91 (1995), 1314–1319.
82. [82] Joannides, R., Bellien, J., Thuillez, C., Clinical methods for the evaluation of endothelial function − a focus on resistance arteries. Fundam. Clin. Pharmacol. 20 (2006), 311–320, 10.1111/j.1472-8206.2006.00406.x.
83. [83] Benjamin, N., Calver, A., Collier, J., Robinson, B., Vallance, P., Webb, D., Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 25 (1995), 918–923, 10.1161/01.HYP.25.5.918.
84. [84] Kuvin, J.T., Patel, A.R., Sliney, K.A., Pandian, N.G., Sheffy, J., Schnall, R.P., et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am. Heart J. 146 (2003), 168–174, 10.1016/S0002-8703(03)00094-2.
85. [85] Bonetti, P.O., Pumper, G.M., Higano, S.T., Holmes, D.R., Kuvin, J.T., Lerman, A., Noninvasive identification of patients with early Coronary atherosclerosis by assessment of digital reactive hyperemia. J. Am. Coll. Cardiol. 44 (2004), 9–13, 10.1016/j.jacc.2004.08.062.
86. [86] Rubinshtein, R., Kuvin, J.T., Soffler, M., Lennon, R.J., Lavi, S., Nelson, R.E., et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur. Heart J. 31 (2010), 1142–1148, 10.1093/eurheartj/ehq010.
87. [87] Nohria, A., Gerhard-herman, M., Creager, M.A., Hurley, S., Mitra, D., Ganz, P., et al. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J. Appl. Physiol. 101 (2006), 545–548, 10.1152/japplphysiol.01285.2005.
88. [88] Hamburg, N.M., Palmisano, J., Larson, M.G., Sullivan, L.M., Lehman, B.T., Vasan, R.S., et al. Relation of brachial and digital measures of vascular function in the community: the framingham heart study. Hypertension 57 (2011), 390–396, 10.1161/HYPERTENSIONAHA.110.160812.
89. [89] Schnabel, R.B., Biener, M.P., Wilde, S., Sinning, C.R., Ojeda, F.M., Zeller, T., et al. Sex differences in noninvasive vascular function in the community. J. Hypertens. 31 (2013), 1437–1446, 10.1097/HJH.0b013e328360f755.
90. [90] Kublickiene, K., Svedas, E., Landgren, B.-M., Crisby, M., Nahar, N., Nisell, H., et al. Small artery endothelial dysfunction in postmenopausal women: in vitro function, morphology, and modification by estrogen and selective estrogen receptor modulators. J. Clin. Endocrinol. Metab. 90 (2005), 6113–6122, 10.1210/jc.2005-0419.
91. [91] Luksha, N., Luksha, L., Carrero, J.J., Hammarqvist, F., Stenvinkel, P., Kublickiene, K., Impaired resistance artery function in patients with end-stage renal disease. Clin. Sci. (Lond.) 120 (2011), 525–536, 10.1042/CS20100277.
92. [92] Celermajer, S., Sorensen, E., Deanfield, E., Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to Coronary risk factors and their interaction. J. Am. Coll. Cardiol. 24 (1994), 1468–1474.
93. [93] Benjamin, E.J., Larson, M.G., Keyes, M.J., Mitchell, G.F., Vasan, R.S., Keaney, J.F., et al. Clinical correlates and heritability of flow-mediated dilation in the community the framingham heart study. Circulation 109 (2004), 613–619, 10.1161/01.CIR.0000112565.60887.1E.
94. [94] Hashimoto, M., Akishita, M., Eto, M., Ishikawa, M., Kozaki, K., Toba, K., et al. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92 (1995), 3431–3435.
95. [95] Williams, M.R.I., Westerman, R.A., Kingwell, B.A., Paige, J., Blombery, P.A., Sudhir, K., et al. Variations in endothelial function and arterial compliance during the menstrual cycle. J. Clin. Endocrinol. Metab. 86 (2001), 5389–5395, 10.1210/jc.86.11.5389.
96. [96] MacRitchie, A.N., Jun, S.S., Chen, Z., German, Z., Yuhanna, I.S., Sherman, T.S., et al. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ. Res. 81 (1997), 355–362.
97. [97] Chambliss, K.L., Shaul, P.W., Estrogen modulation of endothelial nitric oxide synthase. Endocr. Rev. 23 (2002), 665–686, 10.1210/er.2001-0045.
98. [98] Lu, Q., Pallas, D.C., Surks, H.K., Baur, W.E., Mendelsohn, M.E., Karas, R.H., Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 17126–17131, 10.1073/pnas.0407492101.
99. [99] Egan, K.M., a, Lawson J, Fries, S., Koller, B., Rader, D.J., Smyth, E.M., et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306 (2004), 1954–1957, 10.1177/153100350501700320.
100. [100] Bekesi, G., Tulassay, Z., Racz, K., Feher, J., Szekacs, B., Kakucs, R., et al. The effect of estrogens on superoxide anion generation by human neutrophil granulocytes: possible consequences of the antioxidant defense. Gynecol. Endocrinol. 23 (2007), 451–454, 10.1080/09513590701483951.
101. [101] Bhangoo, A., Rosenbaum, M., Endothelial function as measured by peripheral arterial tonometry increases during pubertal advancement. Horm. Res. Paediatr 76 (2011), 226–233, 10.1159/000328455.
102. [102] Deda, L., Sochett, E.B., Mahmud, F.H., Physiological changes in blood pressure impact peripheral endothelial function during adolescence. Cardiol. Young 2014 (2016), 1–3, 10.1017/S1047951114001024.
103. [103] Marlatt, K.L., Steinberger, J., Dengel, D.R., Sinaiko, A., Moran, A., Chow, L.S., et al. Impact of pubertal development on endothelial function and arterial elasticity. J. Pediatr. 163 (2013), 1432–1436, 10.1016/j.jpeds.2013.07.002.
104. [104] Schnabel, R.B., Schulz, A., Wild, P.S., Sinning, C.R., Wilde, S., Eleftheriadis, M., et al. Noninvasive vascular function measurement in the community cross-sectional relations and comparison of methods. Circ. Cardiovasc. Imag. 4 (2011), 371–380, 10.1161/CIRCIMAGING.110.961557.
105. [105] Celermajer, D.S., Sorensen, K.E., Spiegelhalter, D.J., Georgakopoulos, D., Robinson, J., Deanfield, J.E., Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J. Am. Coll. Cardiol. 24 (1994), 471–476, 10.1016/0735-1097(94)90305-0.
106. [106] Moreau, K.L., Hildreth, K.L., Meditz, A.L., Deane, K.D., Kohrt, W.M., Endothelial function is impaired across the stages of the menopause transition in healthy women. J. Clin. Endocrinol. Metab. 97 (2012), 4692–4700, 10.1210/jc.2012-2244.
107. [107] Gilligan, D.M., Quyyumi, A., Cannon, R.O., Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89 (1994), 2545–2551, 10.1161/01.CIR.89.6.2545.
108. [108] Saitta, A., Altavilla, D., Cucinotta, D., Morabito, N., Frisina, N., Corrado, F., et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 21 (2001), 1512–1519, 10.1161/hq0901.095565.
109. [109] Kublickiene, K., Svedas, E., Landgren, B.M., Crisby, M., Nahar, N., Nisell, H., et al. Small artery endothelial dysfunction in postmenopausal women: in vitro function, morphology, and modification by estrogen and selective estrogen receptor modulators. J. Clin. Endocrinol. Metab. 90 (2005), 6113–6122, 10.1210/jc.2005-0419.
110. [110] Bechlioulis, A., Naka, K.K., Kalantaridou, S.N., Chatzikyriakidou, A., Papanikolaou, O., Kaponis, A., et al. Short-term hormone therapy improves sCD40L and endothelial function in early menopausal women: potential role of estrogen receptor polymorphisms. Maturitas 71 (2012), 389–395, 10.1016/j.maturitas.2012.01.001.
111. [111] Akman, L., Duygu, H., Akercan, F., Ulukus, M., Ozerkan, F., Akin, M., The effects of different hormone treatment on endothelial function in healthy postmenopausal women. Gynecol. Endocrinol. 29 (2013), 867–872, 10.3109/09513590.2013.813471.
112. [112] Ketel, I.J.G., Stehouwer, C.D.A., Serné, E.H., Poel, D.M., Groot, L., Kager, C., et al. Microvascular function has no menstrual-cycle-dependent variation in healthy ovulatory women. Microcirculation 16 (2009), 714–724, 10.3109/10739680903199186.
113. [113] Adkisson, E.J., Casey, D.P., Beck, D.T., Gurovich, A.N., Martin, J.S., Braith, R.W., Central, peripheral and resistance arterial reactivity: fluctuates during the phases of the menstrual cycle. Exp. Biol. Med. 235 (2010), 111–118, 10.1258/ebm.2009.009186 Central.
114. [114] Vehkavaara, S., Hakala-Ala-Pietila, T., Virkamaki, A., Bergholm, R., Ehnholm, C., Hovatta, O., et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 102 (2000), 2687–2693.
115. [115] Sanada, M., Higashi, Y., Nakagawa, K., Tsuda, M., Kodama, I., Nagai, N., et al. Combination therapy of low-dose medroxyprogesterone acetate and oral estrogen does not affect endothelial function in the forearms of postmenopausal women. Menopause 9 (2002), 360–366, 10.1097/01.GME.0000032673.61400.8A.
116. [116] Kling, J.M., Lahr, B.A., Bailey, K.R., Harman, S.M., Miller, V.M., Mulvagh, S.L., Endothelial function in women of the kronos early estrogen prevention study. Climacteric 18 (2015), 187–197, 10.3109/13697137.2014.986719.
117. [117] McCrohon, J.A., Walters, W.A., Robinson, J.T., McCredie, R.J., Turner, L., Adams, M.R., et al. Arterial reactivity is enhanced in genetic males taking high dose estrogens. J. Am. Coll. Cardiol. 29 (1997), 1432–1436.
118. [118] New, G., Timmins, K.L., Duffy, S.J., Tran, B.T., O'Brien, R.C., Harper, R.W., et al. Long-term estrogen therapy improves vascular function in male to female transsexuals. J. Am. Coll. Cardiol. 29 (1997), 1437–1444.
119. [119] New, G., Duffy, S.J., Harper, R.W., Meredith, I.T., Long-term oestrogen therapy is associated with improved endothelium-dependent vasodilation in the forearm resistance circulation of biological males. Clin. Exp. Pharmacol. Physiol. 27 (2000), 25–33.
120. [120] Lew, R., Komesaroff, P., Williams, M., Dawood, T., Sudhir, K., Endogenous estrogens influence endothelial function in young men. Circ. Res. 93 (2003), 1127–1133, 10.1161/01.RES.0000103633.57225.BC.
121. [121] Saltiki, K., Papageorgiou, G., Voidonikola, P., Mantzou, E., Xiromeritis, K., Papamichael, C., et al. Endogenous estrogen levels are associated with endothelial function in males independently of lipid levels. Endocrine 37 (2010), 329–335, 10.1007/s12020-010-9307-7.
122. [122] Kublickiene, K., Luksha, L., Gender and the endothelium. Pharmacol. Rep. 60 (2008), 49–60.
123. [123] Zhao, C., Dahlman-Wright, K., Gustafsson, J.-A., Estrogen receptor beta: an overview and update. Nucl. Recept Signal., 6, 2008, e003, 10.1621/nrs.06003.
124. [124] Yu, J., Akishita, M., Eto, M., Ogawa, S., Son, B.K., Kato, S., et al. Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/Akt pathway. Endocrinology 151 (2010), 1822–1828, 10.1210/en.2009-1048.
125. [125] Alexandersen, P., Haarbo, J., Christiansen, C., The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 125 (1996), 1–13.
126. [126] Webb, C.M., Mcneill, J.G., Hayward, C.S., De Zeigler, D., Collins, P., Effects of testosterone on Coronary vasomotor regulation in men with Coronary heart disease. Circulation 100 (1999), 1690–1697.
127. [127] Akishita, M., Hashimoto, M., Ohike, Y., Ogawa, S., Iijima, K., Eto, M., et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens. Res. 30 (2007), 1029–1034, 10.1291/hypres.30.1029.
128. [128] Empen, K., Lorbeer, R., Dorr, M., Haring, R., Nauck, M., Glaser, S., et al. Association of testosterone levels with endothelial function in men: results from a population-based study. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 481–486, 10.1161/ATVBAHA.111.232876.
129. [129] Novo, S., Iacona, R., Bonomo, V., Evola, V., Corrado, E., Di, M., et al. Erectile dysfunction is associated with low total serum testosterone levels and impaired flow-mediated vasodilation in intermediate risk men according to the Framingham risk score. Atherosclerosis 238 (2015), 415–419, 10.1016/j.atherosclerosis.2014.12.007.
130. [130] Yilmaz, M.I., Sonmez, A., Qureshi, A.R., Saglam, M., Stenvinkel, P., Yaman, H., et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin. J. Am. Soc. Nephrol. 6 (2011), 1617–1625, 10.2215/CJN.10681210.
131. [131] Farias, J.M., Tinetti, M., Khoury, M., Umpierrez, G.E., Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 99 (2016), 4698–4703, 10.1210/jc.2014-2585.
132. [132] Ong, P.J., Patrizi, G., Chong, W.C., Webb, C.M., Hayward, C.S., Collins, P., Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am. J. Cardiol. 85 (2000), 269–272.
133. [133] Kang, S.M., Jang, Y., i-Y, Kim J., Chung, N., Cho, S.Y., Chae, J.S., et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am. J. Cardiol. 89 (2002), 862–864.
134. [134] Corrigan, F.E., Al, I., Eapen, D.J., Hayek, S.S., Sher, S., Martin, G.S., et al. Low testosterone in men predicts impaired arterial elasticity and microvascular function. Int. J. Cardiol. 194 (2015), 94–99, 10.1016/j.ijcard.2015.05.065.
135. [135] Francomano, D., Bruzziches, R., Barbaro, G., Lenzi, A., Aversa, A., Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J. Endocrinol. Invest. 37 (2014), 401–411, 10.1007/s40618-014-0066-9.
136. [136] Kenny, A.M., Prestwood, K.M., Gruman, C.A., Fabregas, G., Biskup, B., Mansoor, G., Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J. Gerontol. A Biol. Sci. Med. Sci. 57 (2002), M460–5.
137. [137] McCrohon, J.A., Jessup, W., Handelsman, D.J., Celermajer, D.S., Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 99 (1999), 2317–2322.
138. [138] McCrohon, J.A., Death, A.K., Nakhla, S., Jessup, W., Handelsman, D.J., Stanley, K.K., et al. Androgen receptor expression is greater in macrophages from male than from female donors: a sex difference with implications for atherogenesis. Circulation 101 (2000), 224–226.
139. [139] Sader, M.A., Griffiths, K.A., Mccredie, R.J., Bs, C., Handelsman, D.J., Celermajer, D.S., Androgenic anabolic steroid an arterial structure and function in male bodybuilders. J. Am. Coll. Cardiol., 37, 2000, 9.
140. [140] Sader, M.A., McCredie, R.J., Griffiths, K.A., Wishart, S.M., Handelsman, D.J., Celermajer, D.S., Oestradiol improves arterial endothelial function in healthy men receiving testosterone. Clin. Endocrinol. (Oxf.) 54 (2001), 175–181.
141. [141] Herman, S.M., Robinson, J.T., McCredie, R.J., Adams, M.R., Boyer, M.J., Celermajer, D.S., Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler. Thromb. Vasc. Biol. 17 (1997), 2004–2009.
142. [142] Makinen, J.J.I., Perheentupa, A., Irjala, K., Pollanen, P., Makinen, J.J.I., Huhtaniemi, I., et al. Endogenous testosterone and brachial artery endothelial function in middle-aged men with symptoms of late-onset hypogonadism. Aging Male 14 (2011), 237–242, 10.3109/13685538.2011.593655.
143. [143] Bernini, G., Versari, D., Moretti, A., Virdis, A., Ghiadoni, L., Bardini, M., et al. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy. J. Clin. Endocrinol. Metab. 91 (2006), 1691–1697, 10.1210/jc.2005-1398.
144. [144] Montalcini, T., Gorgone, G., Gazzaruso, C., Sesti, G., Perticone, F., Pujia, A., Endogenous testosterone and endothelial function in postmenopausal women. Coron. Artery Dis. 18 (2007), 9–13, 10.1097/01.mca.0000236290.79306.d1.
145. [145] Rech, Z., Clapauch, R., Grac, M., Low testosterone levels are associated with endothelial dysfunction in oophorectomized early postmenopausal women. Eur. J. Endocrinol. 174 (2016), 297–306, 10.1530/EJE-15-0878.
146. [146] Worboys, S., Kotsopoulos, D., Teede, H., Grath, B.M.C., Davis, S.R., Jean, T., et al. Vasodilation in postmenopausal women already receiving estrogen. J. Clin. Endocrinol. Metab. 86 (2001), 158–161.
147. [147] Shokeir, T., El-Kannishy, G., The effects of laparoscopic ovarian drilling on flow mediated dilation in women with PCOS: relationship with insulin resistance and IGF-I. Minerva Ginecol. 66 (2014), 209–218.
148. [148] Studen, K.B., Sebestjen, M., Pfeifer, M., Prezelj, J., Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur. J. Endocrinol. 164 (2011), 389–395, 10.1530/EJE-10-0709.
149. [149] Ehrmann, D.A., Polycystic ovary syndrome. N. Engl. J. Med. 352 (2005), 1223–1236, 10.1056/NEJMra041536.
150. [150] Norman, R.J., Dewailly, D., Legro, R.S., Hickey, T.E., Polycystic ovary syndrome. Lancet (London, England) 370 (2007), 685–697, 10.1016/S0140-6736(07)61345-2.
151. [151] Brassard, M., AinMelk, Y., Baillargeon, J.-P., Basic infertility including polycystic ovary syndrome. Med. Clin. North Am. 92:xi (2008), 1163–1192, 10.1016/j.mcna.2008.04.008.
152. [152] Legro, R.S., Kunselman, A.R., Dodson, W.C., Dunaif, A., Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84 (1999), 165–169, 10.1210/jcem.84.1.5393.
153. [153] Teede, H.J., Hutchison, S., Zoungas, S., Meyer, C., Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine 30 (2006), 45–53, 10.1385/ENDO:30:1:45.
154. [154] Diamanti-Kandarakis, E., Alexandraki, K., Piperi, C., Protogerou, A., Katsikis, I., Paterakis, T., et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur. J. Clin. Invest. 36 (2006), 691–697, 10.1111/j.1365-2362.2006.01712.x.
155. [155] Lorenz, L.B., Wild, R.A., Polycystic ovarian syndrome: an evidence-based approach to evaluation and management of diabetes and cardiovascular risks for today's clinician. Clin. Obstet. Gynecol. 50 (2007), 226–243, 10.1097/GRF.0b013e31802f5197.
156. [156] Luque-Ramirez, M., Escobar-Morreale, H.F., Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity. Curr. Hypertens. Rep., 16, 2014, 500, 10.1007/s11906-014-0500-6.
157. [157] Corti, R., Hutter, R., Badimon, J.J., Fuster, V., Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J. Thromb. Thromb. 17 (2004), 35–44, 10.1023/B:THRO.0000036027.39353.70.
158. [158] Yang, B., Li, M., Chen, B., Xu, Y., Li, T.-D., Deterioration of endothelial function and carotid intima-media thickness in Tibetan male adolescents exposed to second-hand smoke. J. Renin Angiotensin Aldosterone Syst. 13 (2012), 413–419, 10.1177/1470320312440901.
159. [159] Soyman, Z., Noyan, V., Tulmac, M., Yucel, A., Sagsoz, N., Bayrak, T., et al. Serum paraoxonase 1 activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilatation in women with polycystic ovary syndrome. Fertil. Steril. 95 (2011), 1067–1072, 10.1016/j.fertnstert.2010.12.011.
160. [160] Kelly, C.J.G., Speirs, A., Gould, G.W., Petrie, J.R., Lyall, H., Connell, J.M.C., Altered vascular function in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87 (2002), 742–746, 10.1210/jcem.87.2.8199.
161. [161] Mak, W., Dokras, A., Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. Semin. Thromb. Hemost. 35 (2009), 613–620, 10.1055/s-0029-1242715.
162. [162] Karoli, R., Fatima, J., Siddiqi, Z., Vatsal, P., Sultania, A.R., Maini, S., Study of early atherosclerotic markers in women with polycystic ovary syndrome. Ind. J. Endocrinol. Metab. 16 (2012), 1004–1008, 10.4103/2230-8210.103021.
163. [163] Guleria, A.K., Syal, S.K., Kapoor, A., Kumar, S., Tiwari, P., Dabadghao, P., Cardiovascular disease risk in young Indian women with polycystic ovary syndrome. Gynecol. Endocrinol. 30 (2014), 26–29, 10.3109/09513590.2013.831835.
164. [164] Rajendran, S., Willoughby, S.R., Chan, W.P.A., Liberts, E.A., Heresztyn, T., Saha, M., et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 204 (2009), 509–514, 10.1016/j.atherosclerosis.2008.09.010.
165. [165] Sprung, V.S., Atkinson, G., Cuthbertson, D.J., Pugh, C.J.A., Aziz, N., Green, D.J., et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies. Clin Endocrinol. (Oxf.) 78 (2013), 438–446, 10.1111/j.1365-2265.2012.04490.x.
166. [166] Huber-Buchholz, M.M., Carey, D.G., Norman, R.J., Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J. Clin. Endocrinol. Metab. 84 (1999), 1470–1474, 10.1210/jcem.84.4.5596.
167. [167] Harwood, K., Vuguin, P., DiMartino-Nardi, J., Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm. Res. 68 (2007), 209–217, 10.1159/000101538.
168. [168] Palomba, S., Falbo, A., Zullo, F., Orio, F.J., Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev. 30 (2009), 1–50, 10.1210/er.2008-0030.
169. [169] Kaya, M.G., Yildirim, S., Calapkorur, B., Akpek, M., Unluhizarci, K., Kelestimur, F., Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecol. Endocrinol. 31 (2015), 401–405, 10.3109/09513590.2015.1006188.
170. [170] Bayram, F., Kocer, D., Ozsan, M., Muhtaroglu, S., Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. Gynecol. Endocrinol. 28 (2012), 497–501, 10.3109/09513590.2011.569607.
171. [171] Kocer, D., Bayram, F., Diri, H., The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol. Endocrinol. 30 (2014), 367–371, 10.3109/09513590.2014.887063.
172. [172] Victor, V.M., Rovira-Llopis, S., Banuls, C., Diaz-Morales, N., Lopez-Domenech, S., Escribano-Lopez, I., et al. Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients. Atherosclerosis 242 (2015), 167–173, 10.1016/j.atherosclerosis.2015.07.017.
173. [173] Weiner, C.P., Thompson, L.P., Nitric oxide and pregnancy. Semin. Perinatol. 21 (1997), 367–380.
174. [174] Steegers, E.A.P., Von Dadelszen, P., Duvekot, J.J., Pijnenborg, R., Pre-eclampsia. Lancet 376 (2010), 631–644, 10.1016/S0140-6736(10)60279-6.
175. [175] Say, L., Chou, D., Gemmill, A., Tunçalp, Ö., Moller, A.B., Daniels, J., et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob. Heal. 2 (2014), 323–333, 10.1016/S2214-109X(14)70227-X.
176. [176] Hannaford, P., Ferry, S., Hirsch, S., Cardiovascular sequelae of toxaemia of pregnancy. Heart 77 (1997), 154–158.
177. [177] Smith, G.C., Pell, J.P., Walsh, D., Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet (London, England) 357 (2001), 2002–2006, 10.1016/S0140-6736(00)05112-6.
178. [178] Bellamy, L., Casas, J.-P., Hingorani, A.D., Williams, D.J., Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ, 335, 2007, 974, 10.1136/bmj.39335.385301.BE.
179. [179] Roberts, J.M., Taylor, R.N., Musci, T.J., Rodgers, G.M., Hubel, C.A., McLaughlin, M.K., Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol. 161 (1989), 1200–1204.
180. [180] Brown, M.A., Zammit, V.C., Lowe, S.A., Capillary permeability and extracellular fluid volumes in pregnancy-induced hypertension. Clin. Sci. (Lond.) 77 (1989), 599–604.
181. [181] Roberts, J.M., Edep, M.E., Goldfien, A., Taylor, R.N., Sera from preeclamptic women specifically activate human umbilical vein endothelial cells in vitro: morphological and biochemical evidence. Am. J. Reprod. Immunol. 27 (1992), 101–108.
182. [182] Taylor, R.N., Crombleholme, W.R., Friedman, S.A., Jones, L.A., Casal, D.C., Roberts, J.M., High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am. J. Obstet. Gynecol. 165 (1991), 895–901.
183. [183] Aalkjaer, C., Danielsen, H., Johannesen, P., Pedersen, E.B., Rasmussen, A., Mulvany, M.J., Abnormal vascular function and morphology in pre-eclampsia: a study of isolated resistance vessels. Clin. Sci. (Lond.) 69 (1985), 477–482.
184. [184] Roberts, J.M., Redman, C.W., Pre-eclampsia: more than pregnancy-induced hypertension. Lancet (London, England) 341 (1993), 1447–1451.
185. [185] Ashworth, J.R., Warren, A.Y., Johnson, I.R., Baker, P.N., Plasma from pre-eclamptic women and functional change in myometrial resistance arteries. Br. J. Obstet. Gynaecol. 105 (1998), 459–461.
186. [186] Svedas, E., Islam, K.B., Nisell, H., Kublickiene, K.R., Vascular endothelial growth factor induced functional and morphologic signs of endothelial dysfunction in isolated arteries from normal pregnant women. Am. J. Obstet. Gynecol. 188 (2003), 168–176.
187. [187] VanWijk, M.J., Kublickiene, K., Boer, K., VanBavel, E., Vascular function in preeclampsia. Cardiovasc. Res. 47 (2000), 38–48.
188. [188] Horstman, L.L., Jy, W., Jimenez, J.J., Ahn, Y.S., Endothelial microparticles as markers of endothelial dysfunction. Front. Biosci. 9 (2004), 1118–1135.
189. [189] Kublickiene, K.R., Lindblom, B., Kruger, K., Nisell, H., Preeclampsia: evidence for impaired shear stress-mediated nitric oxide release in uterine circulation. Am. J. Obstet. Gynecol. 183 (2000), 160–166, 10.1067/mob.2000.105820.
190. [190] VanWijk, M.J., Svedas, E., Boer, K., Nieuwland, R., Vanbavel, E., Kublickiene, K.R., Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am. J. Obstet. Gynecol. 187 (2002), 1686–1693, 10.1067/mob.2002.127905.
191. [191] Luksha, L., Nisell, H., Luksha, N., Kublickas, M., Hultenby, K., Kublickiene, K., Endothelium-derived hyperpolarizing factor in preeclampsia: heterogeneous contribution, mechanisms, and morphological prerequisites. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294 (2008), 510–519, 10.1152/ajpregu.00458.2007.
192. [192] Buemi, M., Allegra, A., Anna, R.D., Coppolino, G., Crascì, E., Giordano, D., et al. Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hyper tension. Am. J. Obstet. Gynecol. 196:68 (2007), e1–68, 10.1016/j.ajog.2006.08.032 e6.
193. [193] Calcaterra, F., Taddeo, A., Colombo, E., Cappelletti, M., Martinelli, A., Calabrese, S., et al. Reduction of maternal circulating endothelial progenitor cells in human pregnancies with intrauterine growth restriction. Placenta 35 (2014), 431–436, 10.1016/j.placenta.2014.04.003.
194. [194] Luppi, P., Powers, R.W., Verma, V., Edmunds, L., Plymire, D., Hubel, C.A., Progenitor cells increase during normal pregnancy but are reduced in women with preeclampsia. Reprod. Sci. 133 (2016), 643–652.
195. [195] Sattar, N., Greer, I.A., Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?. BMJ 325 (2002), 157–160.
196. [196] Chambers, J.C., Fusi, L., Malik, I.S., Haskard, D.O., Swiet, M., Kooner, J.S., Association of maternal endothelial dysfunction with preeclampsia. JAMA 285 (2001), 1607–1612.
197. [197] Ramsay, J.E., Stewart, F., Greer, I.A., Sattar, N., Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG 110 (2003), 1029–1031.
198. [198] Germain, A.M., Romanik, M.C., Guerra, I., Solari, S., Reyes, M.S., Johnson, R.J., et al. Endothelial dysfunction: a link among preeclampsia recurrent pregnancy loss, and future cardiovascular events?. Hypertension 49 (2007), 90–95, 10.1161/01.HYP.0000251522.18094.d4.
199. [199] Hamad, R.R., Eriksson, M.J., Silveira, A., Hamsten, A., Bremme, K., Decreased flow-mediated dilation is present 1 year after a pre-eclamptic pregnancy. J. Hypertens. 25 (2007), 2301–2307, 10.1097/HJH.0b013e3282ef5fc0.
200. [200] Yinon, Y., Kingdom, J.C.P., Odutayo, A., Moineddin, R., Drewlo, S., Lai, V., et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 122 (2010), 1846–1853, 10.1161/CIRCULATIONAHA.110.948455.
201. [201] Agatisa, P.K., Ness, R.B., Roberts, J.M., Costantino, J.P., Kuller, L.H., McLaughlin, M.K., Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am. J. Physiol. Heart Circ. Physiol. 286 (2004), H1389–93, 10.1152/ajpheart.00298.2003.
202. [202] Lampinen, K.H., Ronnback, M., Kaaja, R.J., Groop, P.-H., Impaired vascular dilatation in women with a history of pre-eclampsia. J. Hypertens. 24 (2006), 751–756, 10.1097/01.hjh.0000217859.27864.19.
203. [203] Lommerse, T., Aardenburg, R., Houben, A., Peeters, L.L., Endothelium-dependent vasodilatation in formerly preeclamptic women correlates inversely with body mass index and varies independently of plasma volume. Reprod. Sci. 14 (2007), 765–770, 10.1177/1933719107308336.
204. [204] Evans, C.S., Gooch, L., Flotta, D., Lykins, D., Powers, R.W., Landsittel, D., et al. Cardiovascular system during the postpartum state in women with a history of preeclampsia. Hypertens (Dallas, Tex 1979) 58 (2011), 57–62, 10.1161/HYPERTENSIONAHA.111.173278.
205. [205] Mangos, G.J., Spaan, J.J., Pirabhahar, S., Brown, M.A., Markers of cardiovascular disease risk after hypertension in pregnancy. J. Hypertens. 30 (2012), 351–358, 10.1097/HJH.0b013e32834e5ac7.
206. [206] Navaratnam, K., Alfirevic, Z., Baker, P.N., Gluud, C., Grüttner, B., Kublickiene, K., et al. A multi-centre phase IIa clinical study of predictive testing for preeclampsia: improved pregnancy outcomes via early detection (IMPROvED). BMC Pregnancy Childbirth, 13, 2013, 226, 10.1186/1471-2393-13-226.
207. [207] Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., et al. Chronic kidney disease: global dimension and perspectives. Lancet 382 (2013), 260–272, 10.1016/S0140-6736(13)60687-X.
208. [208] Sarnak, M.J., Cardiovascular complications in chronic kidney disease. Am. J. Kidney Dis. 41 (2003), 11–17.
209. [209] Gansevoort, R.T., Correa-Rotter, R., Hemmelgarn, B.R., Jafar, T.H., Heerspink, H.J.L., Mann, J.F., et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet (London, England) 382 (2013), 339–352, 10.1016/S0140-6736(13)60595-4.
210. [210] Vanholder, R., Massy, Z., Argiles, A., Spasovski, G., Verbeke, F., Lameire, N., Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant. 20 (2005), 1048–1056, 10.1093/ndt/gfh813.
211. [211] Briet, M., Burns, K.D., Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications. Clin. Sci. (Lond.) 123 (2012), 399–416, 10.1042/CS20120074.
212. [212] Schiffrin, E.L., Lipman, M.L., Mann, J.F.E., Chronic kidney disease: effects on the cardiovascular system. Circulation 116 (2007), 85–97, 10.1161/CIRCULATIONAHA.106.678342.
213. [213] Thambyrajah, J., Landray, M.J., McGlynn, F.J., Jones, H.J., Wheeler, D.C., Townend, J.N., Abnormalities of endothelial function in patients with predialysis renal failure. Heart 83 (2000), 205–209.
214. [214] Caglar, K., Yilmaz, M.I., Saglam, M., Cakir, E., Kilic, S., Sonmez, A., et al. Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin. Pract. 108 (2008), c233–c240, 10.1159/000120209.
215. [215] Endemann, D.H., Schiffrin, E.L., Endothelial dysfunction. J. Am. Soc. Nephrol. 15 (2004), 1983–1992, 10.1097/01.ASN.0000132474.50966.DA.
216. [216] Zoccali, C., Mallamaci, F., Tripepi, G., Novel cardiovascular risk factors in end-stage renal disease. J. Am. Soc. Nephrol. 15:Suppl. 1 (2004), S77–80.
217. [217] Tonelli, M., Pfeffer, M.A., Kidney disease and cardiovascular risk. Annu. Rev. Med. 58 (2007), 123–139, 10.1146/annurev.med.58.071105.111123.
218. [218] Kuczmarski, J.M., Darocki, M.D., DuPont, J.J., Sikes, R.A., Cooper, C.R., Farquhar, W.B., et al. Effect of moderate-to-severe chronic kidney disease on flow-mediated dilation and progenitor cells. Exp. Biol. Med. (Maywood) 236 (2011), 1085–1092, 10.1258/ebm.2011.011008.
219. [219] Christensen, F.H., Stankevicius, E., Hansen, T., Jorgensen, M.M., Valverde, V.L., Simonsen, U., et al. Flow- and acetylcholine-induced dilatation in small arteries from rats with renovascular hypertension-effect of tempol treatment. Eur. J. Pharmacol. 566 (2007), 160–166, 10.1016/j.ejphar.2007.03.058.
220. [220] Malyszko, J.S., Malyszko, J., Hryszko, T., Kozminski, P., Pawlak, K., Mysliwiec, M., Markers of endothelial damage in patients on hemodialysis and hemodiafiltration. J. Nephrol. 19 (2006), 150–154.
221. [221] Annuk, M., Soveri, I., Zilmer, M., Lind, L., Hulthe, J., Fellstrom, B., Endothelial function, CRP and oxidative stress in chronic kidney disease. J. Nephrol. 18 (2005), 721–726.
222. [222] Yilmaz, M.I., Saglam, M., Carrero, J.J., Qureshi, A.R., Caglar, K., Eyileten, T., et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol. Dial. Transplant. 23 (2008), 959–965, 10.1093/ndt/gfm727.
223. [223] Luksha, L., Stenvinkel, P., Hammarqvist, F., Carrero, J.J., Davidge, S.T., Kublickiene, K., Mechanisms of endothelial dysfunction in resistance arteries from patients with end-stage renal disease. PLoS One, 7, 2012, e36056, 10.1371/journal.pone.0036056.
224. [224] Mills, K.T., Xu, Y., Zhang, W., Bundy, J.D., Chen, C.-S., Kelly, T.N., et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 88 (2015), 950–957, 10.1038/ki.2015.230.
225. [225] Cobo, G., Hecking, M., Port, F.K., Exner, I., Lindholm, B., Stenvinkel, P., et al. Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clin. Sci. (Lond.) 130 (2016), 1147–1163, 10.1042/CS20160047.
226. [226] Carrero, J.J., de Jager, D.J., Verduijn, M., Ravani, P., De Meester, J., Heaf, J.G., et al. Cardiovascular and noncardiovascular mortality among men and women starting dialysis. Clin. J. Am. Soc. Nephrol. 6 (2011), 1722–1730, 10.2215/CJN.11331210.
227. [227] Vikse, B.E., Irgens, L.M., Leivestad, T., Skjaerven, R., Iversen, B.M., Preeclampsia and the risk of end-stage renal disease. N. Engl. J. Med. 359 (2008), 800–809, 10.1097/01.ogx.0000340761.87862.dc.
228. [228] Clayton, J.A., Collins, F.S., Policy NIH to balance sex in cell and animal studies. Nature 509 (2014), 282–283, 10.1038/509282a.
229. [229] Veldhuis, K., Miller, V., Kublickiene, K., Promoting sex and gender to optimize clinical research and healthcare delivery. Maturitas 81 (2015), 333–334, 10.1016/j.maturitas.2015.03.027.
230. [230] Ritz, S.A., Antle, D.M., Côté, J., Deroy, K., Fraleigh, N., Messing, K., et al. First steps for integrating sex and gender considerations into basic experimental biomedical research. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. J. 28 (2014), 4–13, 10.1096/fj.13-233395.